Lepu Biopharma Balance Sheet Health
Financial Health criteria checks 3/6
Lepu Biopharma has a total shareholder equity of CN¥888.7M and total debt of CN¥694.3M, which brings its debt-to-equity ratio to 78.1%. Its total assets and total liabilities are CN¥2.4B and CN¥1.5B respectively.
Key information
78.1%
Debt to equity ratio
CN¥694.30m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥498.43m |
| Equity | CN¥888.70m |
| Total liabilities | CN¥1.50b |
| Total assets | CN¥2.38b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 2157's short term assets (CN¥677.1M) do not cover its short term liabilities (CN¥899.6M).
Long Term Liabilities: 2157's short term assets (CN¥677.1M) exceed its long term liabilities (CN¥596.0M).
Debt to Equity History and Analysis
Debt Level: 2157's net debt to equity ratio (22%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 2157's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2157 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 2157 has less than a year of cash runway if free cash flow continues to grow at historical rates of 15.7% each year.